Curaleaf rebuts Aurora's claims, cites 35% share decline and weak EBITDA

Curaleaf Holdings, Inc.

Aurora shares fell ~35% over past year vs Curaleaf +56%; Curaleaf reiterates substantial premium offer.
Aurora June quarter adj. EBITDA 63% below March quarter; C$5.1M add-backs; cash flow -C$4.4M.
Aurora's cultivation yield 114g/plant per its own filing; Curaleaf claims more than double.
Aurora guides FY2027 revenue near FY2025, gross margin down to mid-high 50s from ~64%.
Curaleaf says Aurora refused NDA and site visit; no substantive deal talks occurred.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.